Dr. James M. McKiernan, MD

Dr. McKiernan practices at Trustees of Columbia University in the City of NY in New York, New York.

Dr. McKiernan's NPI, 1891804746, was assigned on August 30, 2006. Dr. McKiernan graduated from Vagelos College of Physicians and Surgeons in 1993. Dr. McKiernan holds New York license 202833.

Dr. McKiernan's primary practice is Trustees of Columbia University in the City of NY, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. McKiernan's primary practice is Trustees of Columbia University in the City of NY in New York, New York. Dr. McKiernan is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. McKiernan to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McKiernan practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. McKiernan's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. McKiernan is board certified in urology by the American Board of Urology. Dmand AI has Dr. McKiernan's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists bladder removal, enlarged prostate transurethral surgery (TURP), kidney cysts, kidney disease, kidney removal surgery, prostate cancer, urinary endoscopy and urinary tract infection among the conditions Dr. McKiernan treats.

CMS data shows 397 Medicare services from Dr. McKiernan across 8 procedure codes in 2024, for 158 Medicare patients. Medicare paid $63,248 for them.

CMS counts 158 Medicare patients who saw Dr. McKiernan in 2024. The largest group is 75 to 84, with 76 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McKiernan's median patient age at 74, with 24% women.

In 2024, Dr. McKiernan wrote 156 Medicare Part D claims for 48 patients. 82% of them were for generic drugs. CMS names the drug for 88 of them, across 5 drugs with 11 or more claims each, at $9,663 in total drug cost. In 2023, CMS named 34 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. McKiernan for performance year 2024, reported through an alternative payment model (APM). Dr. McKiernan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McKiernan as offering telehealth.

Dmand AI links 300 papers to Dr. McKiernan, published from 2005 to 2025. 2016 was the busiest year, with 14. The most frequent topics are Kidney Neoplasms, Urinary Bladder Neoplasms and Prostatic Neoplasms. Dr. McKiernan has published most often in Urology. Dr. McKiernan's most frequent co-authors are Mitchell Clark Benson, MD, Guarionex Joel Decastro, MD and Christopher Burch Anderson, MD.

Dmand AI links Dr. McKiernan to 4 clinical trials, 3 of them phase 1/2 studies. 1 is still active or recruiting. Conditions studied include Urinary Bladder Neoplasms, Adenoviridae Infections and Carcinoma.

CMS Open Payments shows 123 general payments to Dr. McKiernan from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Fidia Pharma USA Inc. paid the most, $3,200.

Dmand AI lists 18 awards for Dr. McKiernan, most recently New York Magazine: Top Doctors in 2014.

Dr. McKiernan graduated from Vagelos College of Physicians and Surgeons in 1993.

Dr. McKiernan is in network with 8 carriers, including Aetna, Excellus BlueCross BlueShield and MVP Health Care. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.